Skip to content

For Patients

For Providers

Support

|

Kestra CareStation

Your Partner in SCA Risk Management

Join Us at AHA 2025

Booth 4617 | November 7-10 | New Orleans, LA
View Event Highlights
ASSURE-Composition-3

 

GDMT Takes Time. SCD Doesn’t Wait.

The first 90 days after diagnosis carry the highest risk of sudden cardiac death (SCD) in patients with reduced EF (≤35%)—leaving a critical gap in protection as GDMT is titrated to full effect.1
MARC-030A Landing Page, Conference AHA25, factoid card
IMG-026C-Graphic,-SCD-PROTECT-Time-to-Appropriate-Treatment,-Graph
rhythm-tracings-NoGradient_GIF_v8_LD-1

Protecting Against SCD Is Only Half the Story

Anchored by the ASSURE® WCD, the Cardiac Recovery System® (CRS) platform bridges the gap by pairing proven protection with insights to support recovery. 

The Cardiac Recovery System platform:

  • Provides insights that may be helpful in care optimization, including arrhythmia detection (VT/VF, SVT and Bradyarrhythmia) and physiologic trends (heart rate and activity)
  • Extends care team's reach through timely clinical alerts & rapid post-shock support

By combining proven therapy with increased visibility, the CRS platform empowers providers to protect patients and support their recovery as GDMT reaches full effect.  

hfsa-circle_products_opaque-1

Visit Booth 4617 to discover how Kestra is raising the standard for SCA risk management

  1. Duncker D. et al. European Heart Journal. 2025;00:1–10.
  2. Duncker, D., et al. Clin Cardiol. 2017;40(8):586-590.   

THE FUTURE OF SCA RISK MANAGEMENT STARTS HERE

 

AHA SCIENTIFIC SESSIONS 2025

Late-Breaking Science Abstract Presentation

Primary Results from the Post Approval Study of a Next Generation Wearable Cardioverter Defibrillator System: the ACE-PAS Trial 
Monday, November 10, 2025 @ 8:44 AM • Session Location: 211–213

 

The Cardiac Recovery System Platform Redefines SCA Risk Management

Designed for Daily Life

hfsa-circle-garment-female

With the most customizable fit in the category—seven sizes and two styles—the ASSURE system delivers exceptional comfort and compliance.

  • Up to 87% fewer patients experiencing false alarms than competing WCD patients*3,4
* Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.

Insights to Inform Care

hfsa-circle_insights

In real-world use, the ASSURE system identified potentially actionable cardiac events5,6:

  • Detected arrhythmias in 18% of patients, leading to physician-directed clinical intervention

An Extension of Your Care Team

hfsa-circle_physician

Connected services enable timely clinical intervention and patient support.

Download the Cardiac Recovery System Platform Flyer
  1. ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS) NCT05135403, Cohort April 2024.
  2. Arkles, J. et al. J Interv Card Electrophyiol. 2023;66(7):1723-1728
  3. Phukan A. et el. Clinical Impact of Ventricular and Supraventricular Arrhythmia Detection with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024. Chicago, IL
  4. Syed Z. et el. Initial Real-world Experience with a Novel Wearable Cardioverter Defibrillator. American Heart Association Scientific Sessions. Nov, 2024. Chicago, IL

Booth Highlights

Step into the heart of innovation at Booth 4617 and experience the CRS platform as an immersive multimedia experience.

 

IMG-00XXA-Graphic,-cup-beignet,-v3

Featured In-Booth Activity

Coffee & Beignets with ACE-PAS Abstract Authors

Monday, November 10 @ 9:15 AM

Start your morning with coffee, beignets, and scientific insights. Meet the authors behind the abstract, ask questions, and enjoy a moment of connection.

Find Us @ Booth #4617

AHA-Floor-Map

 

Schedule a VIP Meeting @ AHA

Stay Up to Date

Follow us on social:

social-linkedin   social-x   social-facebook

MKT-00163-01_B